Norway· NO-ID_DFCBA5B2-A9EB-41D0-867F-3C7680D3799A
Gazyvaro
A obinutuzumab product containing obinutuzumab, registered in Norway by Roche Registration GmbH. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Obinutuzumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FA03 (obinutuzumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Obinutuzumab · ATC L01FA03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of obinutuzumab costs, country by country.
Normalised to the WHO defined daily dose (35.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Obinutuzumab · price per daily dose (35.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$143.26
The record
At a glance
FEST (Norway)- Active substance
- Obinutuzumab
- Manufacturer
- Roche Registration GmbH
- Country
- Norway (NO)
- ATC code
- L01FA03
- ATC class
- Obinutuzumab
- Defined daily dose
- 35.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_DFCBA5B2-A9EB-41D0-867F-3C7680D3799A
- gtin7613326013352
- no_varenummer5713581 x 40NOK 41706.2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
72 interactions on record for obinutuzumab.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Obinutuzumab · interactions on record
72 records
- 29 severe
- 43 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Obinutuzumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandGazyvaroAbacus Medicine A/S
- BelgiumGazyvaro 1000 mgRoche Registration
- CzechiaGAZYVARORoche Registration GmbH, Grenzach-Wyhlen
- IcelandGazyvaroRoche Registration GmbH*
- PolandGazyvaroRoche Registration GmbH
- SwedenGazyvaro 1000 mg Koncentrat till infusionsvätska, lösningRoche Registration GmbH
- SpainGAZYVARO 1000 mg CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- United KingdomGazyvaro 1000mg/40ml concentrate for solution for infusion vialsOriginalis B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Gazyvaro
- Liechtenstein · Gazyvaro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a503782d-f559-4868-8ec8-f4407b6629b3 GET /v1/drugs/a503782d-f559-4868-8ec8-f4407b6629b3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Obinutuzumab",
"merkevare_id": "ID_DFCBA5B2-A9EB-41D0-867F-3C7680D3799A",
"name_form_strength": "Gazyvaro kons til inf oppl 1000 mg",
"prescription_group": "C"
}See everything about obinutuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.